Subgroup analysis revealed that high-dose PUFA supplementation (≥ 2 g/day) significantly decreased TJC, VAS activity, MS duration, DA28, HAQ score, and ESR but not SJC, VAS pain, or and CRP level (Fig. 6). This evidence concerns the gene CRP and myeloid sarcoma.